TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19074978
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment focusing solely on eating disorder features
Study: 19074978
Drug: Complex cognitive-behavioral
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex cognitive-behavioral treatment addressing mood intolerance, clinical perfectionism, low self-esteem, or interpersonal difficulties
Study: 19074978
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list control condition (8-week period before treatment)
Study: 11286443
Drug: Various treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatments for cluster headaches; specific interventions not detailed; no dosage or duration mentioned.
Study: 29766701
Drug: Topical daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical daily application of a lotion containing N1‐methylspermidine and Sandalore
Study: 24281004
Drug: Dose-escalated weekly
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose-escalated weekly paclitaxel (80-120 mg/m²)
Study: 24281004
Drug: Standard-dose weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose weekly paclitaxel (80 mg/m²)
Study: 22322126
Drug: 4% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% chlorhexidine (CHX) solution applied to the umbilical cord at birth and once daily for up to 14 days along with soap and educational messages promoting handwashing.
Study: 18939344
Drug: Topical Cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Cyclosporin A (Restasis) with intensive prednisolone acetate
Study: 12110996
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg pyridostigmine bromide (PB)
Study: 12110996
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg pyridostigmine bromide (PB)
Study: 31899792
Drug: Gastric atrophy
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric atrophy (defined as a serum level of pepsinogen I <55 μg/L)
Study: 31899792
Drug: Gastric atrophy
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric atrophy and poor oral health interaction
Study: 26944326
Drug: Neostigmine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (50 μg/kg) plus atropine (15 μg/kg)
Study: 22639053
Drug: Fixed-schedule induction
Normalized name: Humalog Mix Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-schedule induction therapy
Study: 22639053
Drug: Individualized induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized induction therapy
Study: 20029377
Drug: 200 g
Normalized name: PEG-200 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 g fructose daily for 2 weeks
Study: 19029205
Drug: Pravastatin (cholesterol-lowering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (cholesterol-lowering drug)
Study: 12211225
Drug: Cetrorelix acetate
Normalized name: Cetrorelix Acetate
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetrorelix acetate (CET/glu, dose: 10 mg peptide base)
Study: 12211225
Drug: Cetrorelix acetate
Normalized name: Cetrorelix Acetate
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetrorelix acetate (CET/wat, dose: 10 mg peptide base)
Study: 12211225
Drug: Cetrorelix acetate
Normalized name: Cetrorelix Acetate
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetrorelix acetate (CET/glu, dose: 5 mg peptide base)
Study: 10768735
Drug: Zafirlukast tablets
Normalized name: Zafirlukast Tablets
DrugBank: Zafirlukast (DB00549)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zafirlukast tablets (Accolate) 20 mg b.i.d.
Study: 10768735
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP) 100 or 200 microg b.i.d.
Study: 1354618
Drug: Bunazosin 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bunazosin 2.0 mg
Study: 27909164
Drug: Single-dose psilocybin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose psilocybin (0.3 mg/kg) with psychotherapy
Study: 18538469
Drug: Degarelix 200
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Degarelix 200 mg initial dose
Study: 18538469
Drug: Degarelix 240
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Degarelix 240 mg initial dose
Study: 12442064
Drug: Insulin twice
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin twice daily (premixed combination of regular human and NPH insulin)
Study: 12442064
Drug: Bedtime NPH
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime NPH insulin combined with daytime sulphonylurea (combination group)
Study: 10616949
Drug: Psychological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological therapy (individual cognitive behavioural therapy and applied relaxation)
Study: 10616949
Drug: Psychological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological therapy (aggregate data across types of treatment)
Study: 10616949
Drug: Psychological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological therapy (12 of the 20 treatment conditions)
Study: 7853954
Drug: Dantrolene (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dantrolene (3 days treatment)
Study: 2006594
Drug: Saline +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline + Propofol 2.5 mg.kg‐1
Study: 2006594
Drug: Alfentanil 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 20 micrograms.kg‐1 + Propofol 2.5 mg.kg‐1
Study: 2006594
Drug: Alfentanil 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 30 micrograms.kg‐1 + Propofol 2.5 mg.kg‐1
Study: 2006594
Drug: Alfentanil 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 30 micrograms.kg‐1 + Propofol 2.5 mg.kg‐1 (Control for Pain)
Study: 6844366
Drug: Timolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol (10 mg)/Hydrochlorothiazide (25 mg)/Amiloride (2.5 mg) preparation
Study: 6844366
Drug: Full explanation
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full explanation for the change in therapy
Study: 6844366
Drug: Simple notification
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple notification of treatment change
Study: 30443679
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha (IFN‐α) administered subcutaneously at a dosage of 15,000 Units for three consecutive days following myocardial infarction in a rat model
Study: 11093698
Drug: Oxygen administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen administration during walks
Study: 9351876
Drug: Pamidronate therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate therapy (60 mg every 3 weeks, administered 4 times)
Study: 8214731
Drug: morphine 2
Normalized name: apomorphine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 2 mg/fentanyl 50 micrograms
Study: 8214731
Drug: morphine 2
Normalized name: apomorphine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 2 mg/fentanyl 100 micrograms
Study: 8214731
Drug: morphine 4
Normalized name: morphine 4 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 4 mg/fentanyl 50 micrograms
Study: 8214731
Drug: morphine 4
Normalized name: morphine 4 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 4 mg/fentanyl 100 micrograms
Study: 31414957
Drug: Acute xenon
Normalized name: xenon
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute xenon inhalation (30% FiXe for 20 min, 50% FiXe for 5 min, 70% FiXe for 2 min)
Study: 31414957
Drug: Chronic xenon
Normalized name: xenon
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic xenon inhalation (70% FiXe for 2 min on 7 consecutive days)
Study: 31414957
Drug: 4 wk
Normalized name: Rheumatrex Dose Pack 12, 4 Wk Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 wk of xenon inhalation (Phase II)
Study: 17311944
Drug: combination muesli
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination muesli
Study: 14967379
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg daily)
Study: 7946164
Drug: Intravenous nitroprusside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroprusside (SNP)
Study: 3284065
Drug: Aza (2.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aza (2.1 mg/kg/d) plus MP (3.6 mg/kg/d tapered to 0.5 mg/kg/d by day 15)
Study: 3284065
Drug: CsA (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA (10 mg/kg/d tapered to 8 mg/kg/d by day 28)
Study: 3284065
Drug: CsA (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA (10 mg/kg/d tapered to 8 mg/kg/d by day 28) plus MP (3.6 mg/kg/d tapered to 0 mg/kg/d by day 9)
Study: 30099395
Drug: Morita Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morita Therapy plus treatment as usual (TAU)
Study: 11078174
Drug: Cortisol (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (oral administration for 2 or 5 days)
Study: 11078174
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral administration for 2 or 5 days)
Study: 1400058
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms of intranasal DDAVP
Study: 30716525
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) with a brain target volume receiving focal radiation therapy in fractions of 1.8 Gy to a total of 50.4 Gy
Study: 26395351
Drug: Daily tooth
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily tooth brushing with 500 ppm fluoride toothpaste, supervised by specially trained dental nurses.
Study: 22538327
Drug: Prostacyclin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostacyclin treatment
Study: 16130055
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen (1 g every sixth hour)
Study: 16130055
Drug: Oral acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen (1 g every sixth hour)
Study: 12404086
Drug: Acute tryptophan
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute tryptophan depletion (ATD) via oral mixture of amino acids
Study: 31606734
Drug: Integrase strand
Normalized name: Integrase strand transfer inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrase strand transfer inhibitors (ISTIs)
Study: 30712404
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of IM olanzapine
Study: 30712404
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg of oral clonidine
Study: 25600568
Drug: Bevacizumab with
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab with second-line chemotherapy (mFOLFOX-6 or FOLFIRI)
Study: 25600568
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (mFOLFOX-6 or FOLFIRI without bevacizumab)
Study: 23831423
Drug: TENS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS treatment for 3 weeks (1 hour per day) on the median nerve region of the most impaired hand
Study: 21966856
Drug: Letrozole, 2.5
Normalized name: Letrozole, 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole, 2.5 mg, oral route for 36 months
Study: 21966856
Drug: Tamoxifen, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen, 20 mg, oral route for 36 months
Study: 19948980
Drug: Hyperglycemia (glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycemia (glucose > or =140 mg/dL) on admission
Study: 19948980
Drug: Hyperglycemia (glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycemia (glucose > or =140 mg/dL) after admission
Study: 19948980
Drug: Hypoglycemia (glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemia (glucose < or =70 mg/dL) on admission
Study: 19948980
Drug: Hypoglycemia (glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemia (glucose < or =70 mg/dL) postadmission
Study: 19948980
Drug: Hypoglycemia redefined
Normalized name: refined almond oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemia redefined as glucose < or =60 mg/dL
Study: 19948980
Drug: Postadmission hypoglycemia
Normalized name: Drugs for treatment of hypoglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postadmission hypoglycemia in insulin-treated patients
Study: 11103165
Drug: LMW heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMW heparin delivered by J-Tip
Study: 11103165
Drug: LMW heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMW heparin delivered by standard needle and syringe
Study: 3746543
Drug: IVIgG (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIgG (both low and high doses)
Study: 2453995
Drug: Lidocaine/prilocaine cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine/prilocaine cream (EMLA) applied topically, 10 g one hour before operation
Study: 31770084
Drug: Bio-sorb® cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio-sorb® cream
Study: 31770084
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no cream)
Study: 21255869
Drug: Nonablative 1550-nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonablative 1550-nm fractional laser therapy
Study: 21255869
Drug: Triple topical
Normalized name: Triple Paste Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple topical therapy (hydroquinone 5%, tretinoin 0.05%, and triamcinolone acetonide 0.1% cream)
Study: 10848682
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (INO) at 4 parts per million
Study: 10848682
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of INO and PEEP at 10 cm H2O
Study: 26586327
Drug: GLP-1 receptor
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 receptor agonist exenatide (acute intervention)
Study: 26586327
Drug: GLP-1 receptor
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 receptor agonist liraglutide (12-week intervention)
Study: 26586327
Drug: DPP-4 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP-4 inhibitor sitagliptin (12-week intervention)
Study: 23896631
Drug: Neoadjuvant chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiation (45.0 Gy and boost up to 54.0 Gy plus concurrent and subsequent gemcitabine)
Study: 20043816
Drug: SB-742457 35
Normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-742457 35 mg
Study: 20043816
Drug: SB-742457 5
Normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-742457 5 mg
Study: 20043816
Drug: SB-742457 15
Normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-742457 15 mg
Study: 17804302
Drug: School-based supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based supervised asthma therapy
Study: 17804302
Drug: Parent supervised
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent supervised asthma therapy
Study: 10192233
Drug: Amlodipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (2.5 to 10 mg/day)
Study: 10192233
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 to 40 mg/day)
Study: 1970027
Drug: Doxapram infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram infusion (2 mg per min for 6 h immediately after surgery and repeated on the first postoperative day)
Study: 1970027
Drug: Doxapram infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram infusion
Study: 24905260
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading (Columbus Bridge Protocol) with 4 to 6 implants, loaded within 24 hours
Study: 24905260
Drug: Delayed loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed loading (two-stage surgical protocol) with 6 to 9 straight implants, loaded a mean of 8.75 months after surgery
Study: 19371389
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment applied (Group G2)
Study: 17911499
Drug: Perindopril (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (8 mg/d for 24 weeks)
Study: 9727729
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg chlorazepate
Study: 9727729
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oxazepam
Study: 2532841
Drug: etretin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: etretin (50 mg/day)
Study: 19445822
Drug: Caffeine alone
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine alone (150 mg)
Study: 19445822
Drug: Caffeine plus
Normalized name: Caffeine Plus Green Tea Extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine plus a catechin mixture (600 mg) enriched in EGCG
Study: 16786231
Drug: On-site fibrin-specific
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-site fibrin-specific thrombolytic therapy (TT)
Study: 14962331
Drug: Roc 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roc 0.4 mg.kg(‐1)
Study: 14962331
Drug: Miv 0.133
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miv 0.133 mg.kg(‐1)
Study: 14962331
Drug: Roc 0.32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roc 0.32 + Miv 0.027 mg.kg(‐1)
Study: 14962331
Drug: Roc 0.24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roc 0.24 + Miv 0.053 mg.kg(‐1)
Study: 14962331
Drug: Roc 0.16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roc 0.16 + Miv 0.08 mg.kg(‐1)
Study: 14962331
Drug: Roc 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roc 0.08 + Miv 0.106 mg.kg(‐1)
Study: 14962331
Drug: Combination groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination groups (Roc + Miv)
Study: 11098963
Drug: Filgrastim 300
Normalized name: FILGRASTIM 300MCG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgrastim 300 microg subcutaneously once daily for 7 days
Study: 9049456
Drug: Electrolyte-poor water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrolyte-poor water supplementation (2 L/day)
Study: 9049456
Drug: HCO3-rich water
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCO3-rich water supplementation (2 L/day, 47.5 mmol/L)
Study: 8075257
Drug: Ampicillin/sulbactam (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin/sulbactam (3 g every 6 hours)
Study: 8075257
Drug: Imipenem/cilastatin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin (500 mg every 6 hours)
Study: 20693570
Drug: Self-reported answer
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported answer to a question about drinking quantity (weekly consumption of 8 or more standard drinks) within the past 90 days
Study: 16098074
Drug: Intensified treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified treatment arm (idarubicin 42 mg/m2, melphalan 200 mg/m2, cyclophosphamide 120 mg/kg)
Study: 16098074
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment arm (melphalan 200 mg/m2)
Study: 10616771
Drug: OAC1w (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC1w (omeprazole 20mg bid + amoxicillin 1000mg bid + clarithromycin 400mg bid for 1 week)
Study: 10616771
Drug: OAC2w (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC2w (omeprazole 20mg bid + amoxicillin 1000mg bid + clarithromycin 400mg bid for 2 weeks)
Study: 8572853
Drug: One-hour course
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-hour course about diet (CC)
Study: 2695413
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium (550 mg twice daily, from day -7 to the 4th day of the cycle)
Study: 321147
Drug: Acetyl strophanthanin
Normalized name: Acetyl sulfisoxazole
DrugBank: Acetyl sulfisoxazole (DB14033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl strophanthanin (0.5 mg initially, followed by 0.25 mg four hours later)
Study: 25664155
Drug: Nefopam 40
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam 40 mg mixed with normal saline 100 ml (Group N)
Study: 23307959
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg PEA, twice a day for three months (T1)
Study: 23307959
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg PEA, after washout period (T3)
Study: 16432054
Drug: L-arginine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine + ramipril
Study: 16432054
Drug: L-NG-nitro-arginine-methyl-ester (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NG-nitro-arginine-methyl-ester (2 mg/kg) during ramipril
Study: 14768658
Drug: Cafeteria-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cafeteria-based intervention including daily activities to increase availability, attractiveness, and encouragement for fruit and vegetable consumption, along with special events over two school years.
Study: 11765593
Drug: Prednisolone 50
Normalized name: prednisolone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 50 mg Ferring tablets (test preparation)
Study: 11765593
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation (control)
Study: 8393019
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (3 x 4 mg)